AGC Biologics to acquire cell and gene therapy manufacturing facility in Longmont, Colorado
The facility will equip AGC Biologics with ‘significant additional capacity’: adding 622,000 square feet of operations and office space within six buildings. It is 16 miles from AGC Biologics’ large-scale stainless steel mammalian facility in Boulder.
AGC Biologics says the new facility will help it expand its end-to-end Cell and Gene Therapy (C>) offering, ensuring security of supply for current and future C> customers. It adds that it plans to hire a 'significant percentage' of the current staff employed by Novartis Gene Therapies at the site
Parent company AGC acquired Italy’s MolMed in 2020 and has since boosted investment in cell and gene therapy technologies: presenting itself as one of a few CDMOs in the world offering end-to-end services in the space.
In February, AGC Biologics also announced an expansion at the Center of Excellence for Cell and Gene Therapy in Milan, Italy: with increased capacities and viral vector suspension capabilities.
